A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
Public ClinicalTrials.gov record NCT00601172. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Study of Single Dose Intravenous Casopitant in Combination With Ondansetron and Dexamethasone for the Prevention of Oxaliplatin Induced Nausea and Vomiting.
Study identification
- NCT ID
- NCT00601172
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 710 participants
Conditions and interventions
Conditions
Interventions
- Casopitant Drug
- Dexamethasone Drug
- Placebo Drug
- Ondansetron Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 9, 2008
- Primary completion
- Apr 12, 2009
- Completion
- Apr 12, 2009
- Last update posted
- Jan 16, 2018
2008 – 2009
United States locations
- U.S. sites
- 23
- U.S. states
- 14
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Hot Springs | Arkansas | 71913 | — |
| GSK Investigational Site | Corona | California | 92879 | — |
| GSK Investigational Site | Fountain Valley | California | 92708 | — |
| GSK Investigational Site | Riverside | California | 92501 | — |
| GSK Investigational Site | St. Petersburg | Florida | 33705 | — |
| GSK Investigational Site | Tampa | Florida | 33614 | — |
| GSK Investigational Site | Alexandria | Louisiana | 71301 | — |
| GSK Investigational Site | Baton Rouge | Louisiana | 70809 | — |
| GSK Investigational Site | Baltimore | Maryland | 21215-5271 | — |
| GSK Investigational Site | Boston | Massachusetts | 02135 | — |
| GSK Investigational Site | Worcester | Massachusetts | 01608 | — |
| GSK Investigational Site | Jefferson City | Missouri | 65109 | — |
| GSK Investigational Site | Great Falls | Montana | 59405 | — |
| GSK Investigational Site | The Bronx | New York | 10467 | — |
| GSK Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| GSK Investigational Site | Hilton Head Island | South Carolina | 29926 | — |
| GSK Investigational Site | Mt. Pleasant | South Carolina | 29464 | — |
| GSK Investigational Site | Sumter | South Carolina | 29150 | — |
| GSK Investigational Site | Corpus Christi | Texas | 78412 | — |
| GSK Investigational Site | Corpus Christi | Texas | 78463-3069 | — |
| GSK Investigational Site | Duncanville | Texas | 75137 | — |
| GSK Investigational Site | Ogden | Utah | 84403 | — |
| GSK Investigational Site | Burlington | Vermont | 05401 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 73 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00601172, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 16, 2018 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00601172 live on ClinicalTrials.gov.